EBV、ki67、ERK1在乳腺癌中的表达及其相关性

在过去50年中乳腺癌发病率呈逐年上升趋势，已跃居女性恶性肿瘤首位，成为威胁女性健康的首要恶性肿瘤。对乳腺癌的病因学研究也就成为热点。在EB病毒（EpsteinBarrvirus，EBV）与乳腺癌的相关性研究中，对EBV是乳腺癌发病病因的结论仍存在争议。增殖核抗原ki67是细胞具有极度增殖活性的表现，被广泛地应用于测定各种肿瘤的增殖活性。MAPK是乳腺癌中重要的调节信号，其细胞外信号调节蛋白激酶（ERK）通路能促进细胞增殖，决定细胞向终末期分化或发生凋亡。本文就近年来EBV、ki67、ERK1与乳腺癌方面的研究进展作一综述。     

Ki67在乳腺癌组织中的表达及其临床意义研究

目的探讨乳腺癌组织Ki67表达水平及其与疾病分型、患者预后等的相关性。方法收集2013年1月至2015年12月于本院治疗的93例乳腺癌患者及20例乳腺良性疾病患者临床资料,分析Ki67指数与疾病病理参数及实验室指标的相关性。结果 93例乳腺癌患者Ki67指数水平为1%~90%,中位数为21.65%。乳腺癌组织学分级、肿瘤直径、人表皮生长因子受体2(HER2)表达状态与Ki67指数相关(P0.05),年龄、绝经状态、肿瘤TNM分期、腋窝淋巴结转移状态、雌激素受体(ER)及孕激素受体(PR)表达状态与Ki67指数无关(P0.05)。三阴性乳腺癌、非三阴性乳腺癌及乳腺良性疾病患者Ki67指数中位数依次为30.15%、20.26%、4.67%,三者间Ki67指数比较差异有统计学意义(P0.05)。Ki67指数水平与乳腺癌分型相关(P0.05),与患者血细胞比容和血钾浓度水平相关(P0.05)。结论 Ki67指数联合其他指标可用于乳腺癌诊治及患者预后判断,具有一定的临床应用价值。     

eIF4E和ki67在子宫内膜异位症中的表达及其临床意义

目的探讨eIF4E和ki67在子宫内膜异位症中的表达及临床意义。方法采用免疫组化技术SP法检测异位内膜组（30例）,在位内膜组（30例）及正常内膜组（20例）中eIF4E及ki67蛋白的表达水平。结果eIF4E和ki67在3组内膜中表达强弱依次为异位内膜>在位内膜>正常内膜,其差异有显著统计学意义（P<0.01）;eIF4E在正常内膜组和在位内膜中分泌期高于增殖期,其差异有显著统计学意义（P<0.05）,ki67在正常内膜组分泌期高于增殖期（P<0.05）,在位内膜组增殖期高于分泌物（P<0.05）;而eIF4E和ki67两者在异位内膜和在位内膜中的表达呈正相关（r=0.861,P<0.01;r=0.788,P<0.01）,在正常内膜表达无明显相关性（r=0.297,P=0.207）。结论eIF4E和ki67在子宫内膜异位症表达明显增高,eIF4E和ki67可能与子宫内膜异位症发生发展密切相关。     

乳腺癌组织中Ki-67与C—erbB-2的表达及其临床意义

目的检测ki-67,C—erbB-2在乳腺癌组织中的表达并探讨临床意义及相关关系。方法应用免疫组化S-P法,检测166例乳腺癌组织中ki-67,C—erbB-2的表达结果,分析其相关关系。结果①阳性表达率：ki-67为79．52％（132／166）,C-erbB-2为66．26％（110／166）;②Ki-67表达强度与C-erbB-2表达强度（X^2=109．79;P〈0．01）呈正相关性。结论ki-67,C—erbB-2在乳腺癌组织中的表达均较高,可作为乳腺癌独立的预后判断因子;联合检测具有实际的临床意义,可作为临床病理因素之外早期识别高转移潜能乳腺癌的重要补充指标。     

免疫组化P16和ki67双表达在宫颈癌前病变及宫颈癌的临床分析

目的 分析在宫颈癌前病变及宫颈癌临床诊断时采取免疫组化P16和ki67双表达方法的临床价值。方法 选取2016年1月—2021年12月宿迁市第一人民医院收治的70例宫颈癌前病变患者作为对照组,另选择同期收治的50例宫颈癌患者作为观察组。两组均以相同的方式检测其病理组织标本中的P16、ki67表达水平,并分析P16、ki67单一检测及联合检测的诊断效能。结果 观察组P16表达量(3.03±0.24)分、ki67表达量(2.11±0.32)分均显著高于对照组,差异有统计学意义(t=75.379、41.008,P<0.05);联合检测真阳性检出率、敏感度、特异度、准确性均显著高于P16单一检测、ki67单一检测,差异有统计学意义(χ²=8.305、7.161、17.472、7.600、11.002,P<0.05)。结论 与宫颈癌前病变患者P16、ki67表达水平相比,宫颈癌患者主要为高表达,联合检测具有更高的诊断效能,因而在临床中的使用价值突出,适合普及。     

dCTP焦磷酸酶在乳腺癌组织中的表达情况及临床意义研究

目的 分析dCTP焦磷酸酶(DCTPP1)在乳腺癌组织中的表达情况及其临床意义.方法 选取2016年6月至2017年12月在本院行手术治疗乳腺癌的女性患者82例,每例标本均取癌组织为癌组织组,取距癌边缘5cm以上的正常组织为癌旁组织组.收集患者的临床及随访资料,包括年龄、肿瘤分级、T分期、淋巴结转移情况、组织类型、雌激...     

ezrin在乳腺癌中的表达及其临床意义

目的 探讨乳腺癌组织中ezrin蛋白的表达及其临床意义.方法 应用免疫组化S-P方法,检测63例乳腺癌组织中ezrin的表达情况.结果 ezrin总的表达率为55.56%(35/63),ezrin表达率随着淋巴结转移增多和临床分期的增高而升高(χ2分别为7.718、6.760,P分别为0.005、0.009).无病生存时间在5年以上患者的ezrin表达率[33.33%(10/30)]显著低于无病生存时间不足5年(远处转移)或5年内死亡的患者(75.76%,25/33,χ2=11.455,P=0.001),但是ezrin的表达和肿瘤大小、月经及年龄无相关性(χ2分别为0.060、0.423、0.319,P均>0.05).结论 检测ezrin在乳腺癌中的表达可能有助于对其预后的判断.     

Ki67表达在乳腺癌新辅助化疗中的临床意义

目的探讨Ki67表达与乳腺癌新辅助化疗（neoadjuvant chemotherapy,NACT）疗效的关系。方法我院2009年6月至2011年3月收治的接受NACT、化疗后可手术的52例乳腺癌患者,采用免疫组化方法检测NACT前后乳腺癌组织中Ki67的表达情况,采用Miler and Payne（MP）治疗反应评价方法评价术后乳腺癌组织的病理治疗反应水平,统计学分析二者间关系。结果Ki67高表达组NACT后病理有效率（67．74％）高于低表达组（23．81％）,Ki67表达明显下降组（65．52％）病理有效率高于轻度下降组（26．09％）,差异均有统计学意义（P〈0．01）。结论Ki67表达水平可以作为乳腺癌NACT的敏感性预测指标,NACT前后Ki67表达下降水平可作为评价化疗效果的重要指标。     

霍奇金淋巴瘤转染mtrⅡ基因后ki67的表达及其意义

目的:探讨ki67在转染mtrⅡ基因后的霍奇金淋巴瘤中的表达情况及其意义.方法:将mtrⅡ转染人霍奇金淋巴瘤细胞系,采用免疫组化法检测转染前后ki67的表达情况.结果:未转染mtrⅡ基因的ki67阳性率为21.3%,转染mtrⅡ基因后ki67的阳性率为36.8%,两者之间差异具有统计学意义(P<0.05).结论:mtrⅡ基因可能参与了霍奇金淋巴瘤恶性转化的过程.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

ezrin在乳腺癌中的表达及其临床意义

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistuchemieal staining(S-P) was used to detect the expression of ezrin in 63 cases of breast car-cinoma samples. Results Among these 63 samples,the total expression rates of ezrin were 55.56% (35/63). With the increasing of axillary lymph nodes metastasis and clinical staging,the rates of expressing of ezrin elevated (P<0.05),which was remarkably lower in patients whose disease-free survival(DFS) was > 5 years,or those whose DFS≤5 years or died within five years(P<0.05) ,but the expression of ezrin was not correlated with tumor size,age and menopausal status (P>0.05). Conclusion The expression of ezrin may contribute to prognostic e-valuation for breast carcinoma.     

p53和Ki-67表达在乳腺癌中的临床意义

目的分析p53、Ki-67在乳腺癌组织中的表达,并探讨其与临床病理特征间的关系。方法采用免疫组织化学染色(SP法)检测58份乳腺癌组织标本中p53、Ki-67的表达情况,并结合临床资料进行分析。结果 p53表达阳性率为60.3%,与患者年龄、绝经与否无明显相关性(P0.05),而与淋巴结转移和TNM分期有相关性(P0.05);Ki-67表达的阳性率为53.4%,与患者年龄、绝经与否、淋巴结转移无明显相关性(P0.05),而与TNM肿瘤分期有相关性(P0.05)。结论 p53、Ki-67阳性表达在乳腺癌组织中具有重要的临床意义,与乳腺癌的发生、发展密切相关。